- Home
- BLFS vs ARQT Comparison
BLFS vs ARQT Comparison
Compare BLFS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- ARQT
- Stock Information
- Founded
- BLFS 1987
- ARQT 2016
- Country
- BLFS United States
- ARQT United States
- Employees
- BLFS N/A
- ARQT N/A
- Industry
- BLFS Medical/Dental Instruments
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- ARQT Health Care
- Exchange
- BLFS Nasdaq
- ARQT Nasdaq
- Market Cap
- BLFS 1.2B
- ARQT 1.1B
- IPO Year
- BLFS 1989
- ARQT 2020
- Fundamental
- Price
- BLFS $27.02
- ARQT $14.34
- Analyst Decision
- BLFS Strong Buy
- ARQT Strong Buy
- Analyst Count
- BLFS 7
- ARQT 4
- Target Price
- BLFS $28.29
- ARQT $15.50
- AVG Volume (30 Days)
- BLFS 406.1K
- ARQT 1.8M
- Earning Date
- BLFS 11-12-2024
- ARQT 11-06-2024
- Dividend Yield
- BLFS N/A
- ARQT N/A
- EPS Growth
- BLFS N/A
- ARQT N/A
- EPS
- BLFS N/A
- ARQT N/A
- Revenue
- BLFS $146,957,000.00
- ARQT $138,708,000.00
- Revenue This Year
- BLFS N/A
- ARQT $208.32
- Revenue Next Year
- BLFS N/A
- ARQT $48.56
- P/E Ratio
- BLFS N/A
- ARQT N/A
- Revenue Growth
- BLFS 16.40
- ARQT 182.84
- 52 Week Low
- BLFS $14.50
- ARQT $2.28
- 52 Week High
- BLFS $28.88
- ARQT $14.93
- Technical
- Relative Strength Index (RSI)
- BLFS 58.39
- ARQT 72.61
- Support Level
- BLFS $26.06
- ARQT $12.07
- Resistance Level
- BLFS $28.35
- ARQT $15.02
- Average True Range (ATR)
- BLFS 1.06
- ARQT 0.96
- MACD
- BLFS 0.01
- ARQT 0.18
- Stochastic Oscillator
- BLFS 65.63
- ARQT 91.64
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.